Junichi Omura

Dr. Junichi Omura

Pulmonary Hypertension Group, Medical Science Liaison, Janssen Pharmaceutica, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AFAndrea L. Frump
Andrea L. Frump
MAMarjorie Albrecht
Marjorie Albrecht
BYBakhtiyor Yakubov
Bakhtiyor Yakubov
SBSandra Breuils-Bonnet
Sandra Breuils-Bonnet
VNValérie Nadeau
Valérie Nadeau
TLTim Lahm
Tim Lahm
Women with pulmonary arterial hypertension (PAH) exhibit better right ventricular (RV) function and survival than men; however, the underlying mechanisms are unknown. We hypothesized that 17β-estradiol (E2), through estrogen receptor α (ER-α), attenuates PAH-induced RV failure (RVF) by upregulating the procontractile and prosurvival peptide apelin via a BMPR2-dependent mechanism. We found that ER-α and apelin expression were decreased in RV homogenates from patients with RVF and from rats with maladaptive (but not adaptive) RV remodeling. RV cardiomyocyte apelin abundance increased in vivo or in vitro after treatment with E2 or ER-α agonist. Studies employing ER-α–null or ER-β–null mice, ER-α loss-of-function mutant rats, or siRNA demonstrated that ER-α is necessary for E2 to upregulate RV apelin. E2 and ER-α increased BMPR2 in pulmonary hypertension RVs and in isolated RV cardiomyocytes, associated with ER-α binding to the Bmpr2 promoter. BMPR2 is required for E2-mediated increases in apelin abundance, and both BMPR2 and apelin are necessary for E2 to exert RV-protective effects. E2 or ER-α agonist rescued monocrotaline pulmonary hypertension and restored RV apelin and BMPR2. We identified what we believe to be a novel cardioprotective E2/ER-α/BMPR2/apelin axis in the RV. Harnessing this axis may lead to novel RV-targeted therapies for PAH patients of either sex.

1 July 2023 in Pulmonary Circulation
Verified
Journal Article
Open access
JOJunichi Omura
Junichi Omura
KKKazuki Kitahara
Kazuki Kitahara
MTMasashi Takano
Masashi Takano
KIKoki Idehara
Koki Idehara
SKSeok‐Won Kim
Seok‐Won Kim
Pulmonary arterial hypertension (PAH) is a fatal disease that often occurs at an early age. In recent years, aggressive treatment with multiple drugs from the early‐stage diagnosis is expected to improve the prognosis. Indeed, a high rate of initial combination therapy and excellent treatment outcomes have been reported from specialized centers for PAH in Japan. However, information on PAH epidemiology, including non‐PAH specialized centers in Japan, is unclear. To address the above, we conducted a retrospective observational cohort study from April 2008 to September 2020 using real‐world evidence from a large‐scale administrative database (Medical Data Vision) to examine baseline characteristics, comorbidities, and treatment profiles of Japanese patients with PAH. Five hundred and eighteen patients with PAH (treatment‐naive PAH, age 67.2 ± 15.9) were identified through our comprehensive approach which combined PAH disease codes, medications, and diagnostic procedures. Moreover, we showed that a larger proportion of patients received monotherapy in their initial treatment (66%) compared to those receiving combination therapy (34%). During the 1‐year follow‐up after PAH diagnosis, 13% of patients increased their PAH medications while other patients either decreased their PAH medications (6%) or discontinued PAH treatment (27%). The 3‐ and 5‐year event‐free survival rates of all‐cause death were 72% and 64%, respectively. This is the first large‐scale administrative database study that provides insights into real‐world PAH management in Japan. This study highlighted a different PAH clinical landscape which included a larger portion of the elderly population, higher initial monotherapy treatment, and lower survival rates than previous studies.

13 October 2022 in JGH Open
Verified
Journal Article
Open access
MAMasanori Atsukawa
Masanori Atsukawa
MTMasashi Takano
Masashi Takano
JOJunichi Omura
Junichi Omura
Background and Aim: Portopulmonary hypertension (PoPH) is a complication associated with portal hypertension. Since the epidemiological study in Japan was limited, this study aimed to investigate the characteristics, treatment patterns, and prognosis of PoPH patients in real‐world data.Methods: The characteristics and treatment patterns of PoPH (n = 386) and portal hypertension without pulmonary arterial hypertension (portal hypertension w/o PAH) (n = 96 463) were analyzed based on the Medical Data Vision (MDV) dataset from April 2008 to September 2020. Survival‐time analyses of emergency hospitalization and mortality were also conducted between matched pair cohorts of PoPH (n = 210) and portal hypertension w/o PAH (n = 840).Results: Among 386 PoPH patients, the Child–Pugh classification of PoPH group comprised patients with Class A (59 [15.3%]), B (109 [28.2%]), and C (42 [10.9%]), and missing (176 [45.6%]). Regarding the feature of PoPH group, the proportion of primary biliary cholangitis (PBC) (13.7%) and splenomegaly (9.8%) was higher compared with portal hypertension w/o PAH group. The survival time of all‐cause hospitalization in PoPH group was shorter than portal hypertension w/o PAH group in matched pair cohort (P < 0.001 by log‐rank test). Of PoPH patients, the frequency of PAH‐specific medicine usage within 90 days was monotherapy of 79 patients (20.5%), combination therapy of 64 patients (16.6%), and PAH‐specific medicine usage of 243 patients (63.0%).Conclusion: This was the first study demonstrating that high proportion of PBC and splenomegaly and a greater risk of hospitalization were observed in PoPH patients based on the analysis using administrative claim database.

28 September 2019 in European Respiratory Journal
Verified
Conference Paper
Closed access
JOJunichi Omura
Junichi Omura
KHKarima Habbout
Karima Habbout
SMSandra Martineau
Sandra Martineau
SBSandra Breuils-Bonnet
Sandra Breuils-Bonnet
VNValérie Nadeau
Valérie Nadeau
SBSébastien Bonnet
Sébastien Bonnet
Background: Right ventricular failure (RVF) is the major prognostic factor in pulmonary arterial hypertension (PAH). Recent Omics analyses have demonstrated the deregulation of several long non-coding RNAs (LncRNAs) in left heart failure, but their role in RVF remains unknown. The LncRNA H19 and its encoded miR-675 have been implicated in both cardiac hypertrophy and fibrosis (2 features of RVF) but never been studied in RVF. Methods and Results: By qRT-PCR, we showed in human RV biopsies obtained from control donors, compensated RV hypertrophy patients (CRVH, Cardiac index > 2.2) and decompensated RV hypertrophy patients (DRVH, PAH patients that died from RVF), that H19 and miR-675 were specifically up-regulated (p<0.001, n=10-12/group) in DRVH. Similar findings were found in the monocrotaline rat (MCT), a model characterized by PAH and DRVH. Interestingly H19/miR-675 up-regulation was RV specific as no change was seen in either the LV or lung of DRVH patients or in MCT. In 70 PAH patients, plasma levels of H19 were up-regulated (p<0.001) and correlated with PAH severity (pulmonary vascular resistance, cardiac index and pro-BNP) and prognosis. Mechanistically, we demonstrated that the up-regulation of H19/miR-675 is associated with reduced 4E-BP1, CaMKII-δ and Mitofusin 2, which were previously reported as H19 or miR-675 direct-targets and implicated in heart failure. Moreover, the down-regulation of H19 inhibited phenylephrine-induced cardiac hypertrophy in H9C2 cardiomyocytes. Conclusions: We demonstrated for the first time that H19 is implicated in the transition from CRVH to DRVH in human RVF. Circulating H19 represents a putative biomarker of RV function in PAH patients.